|
Research and Markets: Worldwide Engineered T-Cell Receptor in Fusion …
Business Wire (press release) This report entitled ‘The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry’ describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell … |
|
This Week in Rheumatology: Gout and the ACR Winter Meeting
MedPage Today … week in rheumatology look for: Gout — it’s on the increase, with potentially serious consequences; B-cell depletion with rituximab shows promise in systemic sclerosis in a new study; The ACR Winter Rheumatology Symposium kicks off in Snowmass, Colo. |
R & D Magazine |
TSRI scientists use new technique to discover two antibodies that protect …
News-Medical.net Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find-relatively quickly and cheaply-antibodies that have a desired effect on cells. The TSRI scientists used the … Preventing cell death from infectionR & D Magazine |
Hematologists join cancer care allianceHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-…
Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven …7thSpace Interactive (press release)Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin l…
Pharmacy group presents awardHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic leukemia and co-existing m…
|
Preventing Cell Death from Infection: Scientists Demonstrate Method to Find …
Infection Control Today Scientists at the Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. The TSRI scientists used the … |
|
2014 Outlook: New Drugs in Hepatitis C, MS, Oncology Are Expected This Year
Atlantic Information Services, Inc. … to approve it (see story, p. 1). Other potential additions, she says, include Teva’s laquinimod, Biogen Idec and Abbott Laboratories’ daclizumab and ocrelizumab from Biogen Idec and Roche. © 2014 by Atlantic Information Services, Inc. All Rights … |
|
Biogen Idec-Aktie: Prall gefüllte Pipeline – Kaufen – Nomura Securties …
AktienCheck Der Fokus von Aktienanalyst M. Ian Somaiya liege für das Börsenjahr 2014 auf den Phase-III MS Daten der USD 2 Mrd.-Chance daclizumab zur Jahresmitte und den anti-LINGO-Phase-II-Daten im vierten Quartal 2014. Aktienanalyst M. Ian Somaiya … |
OncLive |
Anti-CD20 Antibodies Continue to Improve Outlook in CLL
OncLive In 2006, Rituximab became the first anti-CD20 antibody to be approved for the treatment of hematologic malignancies and quickly became part of the armamentarium for the treatment of patients with CLL. “Ofatumumab was approved a few years ago, and … |